active substance: torasemide 1 tablet contains torasemide 10 mg;
Excipients: lactose monohydrate, corn starch, colloidal anhydrous silica, magnesium stearate.
Treatment and prevention of recurrence of edema and / or effusions caused by heart failure.
Dosage & Administration
The recommended initial dose of torasemide – 2.5 mg / day (1/2 tablet or 1/4 Trifas Cor tablets Trifas 10). The antihypertensive effect gradually begins already in the 1st week of treatment and reaches its peak no later than 12 weeks of continuous reception. If during this period, blood pressure normalization is not achieved – torasemide daily dose can be raised to 5 mg. When initially severe hypertension, as well as limited kidney function, you can count on an additional antihypertensive effect by increasing the dose. Do not exceed a daily dose of 5 mg, because it hardly will lead to a further decrease in blood pressure.
Swelling and / or effusion
Treatment started with 5 mg per day of torasemide. Depending on severity of the disease the dose can be increased to 20 mg / day.
200 Trifas dose set individually depending on the degree of severity of renal insufficiency. Therapy should start with 1/4 tablet (corresponding to 50 mg of torasemide). With insufficient urinary excretion dose can be increased to 1/2 tablet Trifasa 200 per day, which corresponds to 100 mg of torasemide and a maximum of 1 tablet per day, which corresponds to 200 mg of torasemide.
Tablets are taken in the morning, with liquid squeezed small amount of liquid. The duration of treatment depends on the disease.
Patients with liver failure. Treatment of these patients should be performed with caution, since torasemide may increase plasma concentrations.
Elderly patients special selection of a dose is not required. Adequate studies on the comparison of the treatment of elderly patients and young adults do not have.
Hypersensitivity to torasemide, sulfonylurea compounds and other ingredients; hypotension; renal failure with anuria; hepatic coma or precoma; hypovolemia, hyponatremia, hypokalemia; expressed micturition disorders (e.g. due to prostatic hypertrophy); lactation.
The drug should not be prescribed during normal or moderate renal insufficiency (creatinine clearance> 30 mL / min and / or the concentration of creatinine in the blood plasma of <3.5 mg / dl) due to the risk of excessive loss of water and electrolytes.